Periodic health examination, 1995 update: 1. Screening for human papillomavirus infection in asymptomatic women. Canadian Task Force on the Periodic Health Examination.
OBJECTIVE
To develop recommendations for practising physicians on the advisability of screening for human papillomavirus (HPV) infection in asymptomatic women.


METHODS
Visual inspection, Papanicolaou testing, colposcopy or cervicography, use of HPV group-specific antigen, DNA hybridization, dot blot technique, Southern blot technique or polymerase chain reaction followed by physical or chemical therapeutic intervention.


RESULTS
Evidence for a link between HPV infection and cervical cancer, sensitivity and specificity of HPV screening techniques, effectiveness of treatments for HPV infection, and the social and economic costs incurred by screening.


METHODS
MEDLINE was searched for articles published between January 1966 to June 1993 with the use of the key words "papillomavirus," "cervix neoplasms," "mass screening," "prospective studies," "prevalence," "sensitivity," "specificity," "human" and "female."


METHODS
Proven cost-effective screening techniques that could lead to decreased morbidity or mortality were given a high value. The evidence-based methods and values of the Canadian Task Force on the Periodic Health Examination were used.


RESULTS
Potential benefits are to prevent cervical cancer and eliminate HPV infection. Potential harmful effects include the creation of an unnecessary burden on the health care system and the labelling of otherwise healthy people as patients with a sexually transmitted disease for which therapy is generally ineffective. Potential costs would include expense of testing, increased use of colposcopy and treatment.


CONCLUSIONS
There is fair evidence to exclude HPV screening (beyond Papanicolaou testing for cervical cancer) in asymptomatic women (grade D recommendation).


RESULTS
The report was reviewed by members of the task force and three external reviewers who were selected to represent different areas of expertise.


BACKGROUND
These guidelines were developed and endorsed by the task force, which is funded by Health Canada and the National Health Research and Development Program. The principal author (K.J.) was supported in part by the National Health Research and Development Program through a National Health Fellowship (AIDS).
Department of Preventive Medicine and Biostatistics, University of Toronto, Ont.
K
K
Johnson
D004279:DNA, Viral / Q000032:analysis; D005260:Female; D006801:Humans; D015151:Immunoblotting; D017403:In Situ Hybridization; D008403:Mass Screening / Q000592:standards*; D065006:Papanicolaou Test; D027383:Papillomaviridae / Q000235:genetics / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D010808:Physical Examination; D012680:Sensitivity and Specificity; D014412:Tumor Virus Infections / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D002583:Uterine Cervical Neoplasms / Q000209:etiology; D014626:Vaginal Smears
D004279:DNA, Viral